Showing 2831-2840 of 3039 results for "".
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- CooperVision’s Michele Andrews, OD, Wins 2019 Theia Excellence Award from Women in Optometryhttps://modernod.com/news/coopervisions-michele-andrews-od-wins-2019-theia-excellence-award-from-women-in-optometry/2477045/For her significant contributions to the advancement of the industry and optometric profession, Michele Andrews, OD, Senior Director of Professional and Academic Affairs, North America, CooperVision, has been named a 2019 recipient of Women in Optometry’s Theia Excellence Awards. Dr. And
- Eyevance Pharmaceuticals Acquires Tobradex ST and Natacynhttps://modernod.com/news/eyevance-pharmaceuticals-acquires-tobradex-st-and-natacyn/2477011/Eyevance Pharmaceuticals has announced the acquisition of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and Natacyn (natamycin ophthalmic suspension) 5% from Novartis. Terms of the deal were not disclosed. “The acquisition of Tobradex ST and Natacyn further
- Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the UShttps://modernod.com/news/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/2477008/Sun Pharmaceutical announced that its dry eye drug Cequa (cyclosporine ophthalmic solution) 0.09% is now commercially available the United States. Cequa, which offers the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in pati
- Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions to Provide Early Detection Systems for Diabetic Eye Diseasehttps://modernod.com/news/intelligent-retinal-imaging-systems-iris-partners-with-remidio-innovative-solutions-to-provide-early-detection-systems-for-diabetic-eye-disease/2476989/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- AAO and Verana Health Accelerate Clinical Trials for Patients with Rare, Sight-Threatening Retinal Diseases Through Verana Trial Connecthttps://modernod.com/news/aao-and-verana-health-accelerate-clinical-trials-for-patients-with-rare-sight-threatening-retinal-diseases-through-verana-trial-connect/2476962/The American Academy of Ophthalmology (AAO) and Verana Health announced that they are now facilitating no-cost genetic testing and counseling for patients with certain inherited retinal diseases through Verana Trial Connect, a powerful cloud-based application that facilitates physician and patien
- GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapyhttps://modernod.com/news/gensight-biologics-reports-evidence-of-gs010-dna-transfer-to-contralateral-eye-of-primates-unilaterally-injected-with-gs010-gene-therapy/2476960/GenSight Biologics reported positive proof of GS010 DNA transfer from one eye to the other eye following unilateral intravitreal injection of primates. In a nonclinical study to investigate the local biodistribution of GS010, tissue samples from the non-injected eye of monkeys that had been unila
- Vision 2020 USA to Hold Annual World Sight Day Briefing on October 17, 2019https://modernod.com/news/vision-2020-usa-to-hold-annual-world-sight-day-briefing-on-october-17-2019/2476939/As part of World Sight Day events, on Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075, in aWashington DC, from noon to 1 p.m. According to Prevent Blindness, by 2050, the impaired and blind populations are projecte